Justin Wasserman
Physical Medicine & Rehabilitation · Bethesda, MDNPI 1952400798
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $40,838 of the $50,525 with a category attached, or 80.8%. Idorsia Pharmaceuticals US Inc accounts for 93.4% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2023 at $23,150 and has fallen 98.1% since, to $431 in 2025. Among physical medicine & rehabilitation clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 172 payments — averaging $293.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Idorsia Pharmaceuticals US Inc$47K
- Biohaven Pharmaceuticals, Inc.$1K
- AbbVie$980
- Orexo US, Inc.$234
- Collegium Pharmaceutical, Inc.$174
- Pfizer$124
- plus $617 from 16 others
What the payments were for
- Consulting fees$1,2002%
- Speaking & faculty fees$40,83881%
- Travel & lodging$5,60611%
- Food & beverage$2,8826%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Idorsia Pharmaceuticals US Inc | 50 | $47,185 |
| Biohaven Pharmaceuticals, Inc. | 3 | $1,212 |
| AbbVie(2 entities) | 54 | $980 |
| Orexo US, Inc. | 14 | $234 |
| Collegium Pharmaceutical, Inc. | 10 | $174 |
| Pfizer | 6 | $124 |
| Vertex | 3 | $95 |
| Lilly USA, LLC | 5 | $92 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $61 |
| Novartis | 4 | $56 |
| Arbor Pharmaceuticals, Inc. | 3 | $46 |
| Biodelivery Sciences International, Inc. | 3 | $44 |
| Amgen | 2 | $40 |
| Merck | 2 | $32 |
| Axsome Therapeutics, Inc. | 1 | $30 |
| Eisai Inc. | 2 | $29 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Antares Pharma, Inc. | 1 | $16 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
| Novo Nordisk | 1 | $14 |
| Tonix Medicines, Inc. | 1 | $14 |
| Zimmer Biomet | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QUVIVIQ$46,720
- NURTEC ODT$1,200
- VRAYLAR$125
- UBRELVY$125
How this compares
$50,525 in reported general payments places this provider in the 95th percentile of 202 physical medicine & rehabilitation providers in Maryland.
See all physical medicine & rehabilitation providers in Maryland →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucyntaTapentadol Hcl | 92 | $89,340 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 353 | $68,804 |
| BelbucaBuprenorphine Hcl | 73 | $47,363 |
| OxycontinOxycodone Hcl | 33 | $19,778 |
| SavellaMilnacipran Hcl | 22 | $17,234 |
| QuviviqDaridorexant Hcl | 24 | $14,670 |
| Sumatriptan Succinate | 47 | $14,055 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 26 | $9,280 |
| VyvanseLisdexamfetamine Dimesylate | 20 | $8,120 |
| Buprenorphine | 16 | $7,678 |
| Gabapentin | 237 | $4,473 |
| BelsomraSuvorexant | 11 | $4,465 |
| Pregabalin | 161 | $4,332 |
| Duloxetine Hcl | 211 | $3,833 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 12 | $3,318 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Nucynta, Belbuca | $174 | $136,704165 claims |
| AbbVieSavella | $980 | $17,23422 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $47,185 | $14,67024 claims |
| MerckBelsomra | $32 | $4,46511 claims |
| Orexo US, Inc.Zubsolv | $234 | $3,31812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 202 physical medicine & rehabilitation providers in Maryland.
Other physical medicine & rehabilitation in Bethesda
- David ReeceBethesda$719K
- Julio GomezBethesda$3K
- John ManorBethesda$2K
- Mark KlaimanBethesda$2K
- Raia MinassianBethesda$1K
- Matthew MillerBethesda$777
- Gurtej SinghCatonsville$205K
- Akhil ChhatreBaltimore$169K
- Vivek SindhiGlen Burnie$33K
- Inai MkandawireOwings Mills$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.